IGBA and WHO collaborate on expanding access to quality-assured generic and biosimilar medicines

For immediate release
Geneva, 30 October 2023

On October 27, 2023, the International Generics and Biosimilars Medicines Association (IGBA), including members of IGBA’s CEO Advisory Committee, met with World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus in Geneva. During the full-day meeting, IGBA company and member association representatives, together with WHO technical experts, discussed steps both organizations can take together to expand global access to generic and biosimilar medicines.

“The meeting was a continuation of the collaborative efforts the WHO and IGBA have taken to expand sustained access to quality-assured generic and biosimilar medicines,” commented Suzette Kox, IGBA’s Secretary General. “One year ago, Dr. Tedros agreed to engage in a structured dialogue with the CEO Advisory Committee Members and to set up a plan of action with IGBA to support the WHO Triple Billion Targets.” Kox added.

“The working meeting with WHO is a clear recognition of our common vision in ensuring that patients have access to the medicines they need, wherever and whenever they may need them”, commented Richard Saynor, Chair of the IGBA CEO Advisory Committee and CEO Sandoz.

“We are committed to work together with WHO and harness the power of collaboration to expand access to medicines”, added Vinita Gupta, Vice-Chair of the CEO Advisory Committee and CEO Lupin.

Shared ambitions include:

- Making sure that we improve the visibility of low-and middle-income country markets, especially to ensure that solutions fit their needs and not just the needs and systems in high-income countries.
- Looking for means to improve the use of automation to better predict potential market failures, such as shortages or other supply disruption.
- Expand the existing tools and globally available policies, such as on regulation of biosimilar medicines, which can be complicated for countries with emerging regulatory capacities.

About IGBA

The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.